Loading...
Loading...
Clovis Oncology
CLVS announced today that the underwriters of
its recently announced public offering of its common stock have
exercised in full their option to purchase an additional 528,846 shares.
The offering, including the sale of the additional shares, is expected
to close on July 14, 2015, subject to customary closing conditions.
Clovis Oncology intends to use the net proceeds of the offering for
general corporate purposes, including commercial planning and sales and
marketing expenses associated with the potential launches of rociletinib
and rucaparib, if approved by the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) in the United States and
the European Union, respectively, funding of its development
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in